Influence of Demographic and Lifestyle Variables on Plasma Magnesium Concentrations and Their Associations with Cardiovascular Risk Factors in a Mediterranean Population

Rocío Barragán 1,2,*, Juan Llopis 3, Olga Portolés 1,2, Jose V. Sorlí 1,2, Oscar Coltell 2,4, Lorenzo Rivas-García 3†, Eva M. Asensio 1,2, Carolina Ortega-Azorí 1,2, Dolores Corella 1,2,*,† and Cristina Sánchez-González 3,†

1 Department of Preventive Medicine and Public Health, School of Medicine, University of Valencia, 46010 Valencia, Spain; rocio.barragan@uv.es (R.B.); olga.portoles@uv.es (O.P.); jose.sorli@uv.es (J.V.S.); eva.m.asensio@uv.es (E.M.A.); Carolina.ortega@uv.es (C.O.-A.)
2 CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain; oscar.coltell@uji.es
3 Department of Physiology, School of Pharmacy, University of Granada, 18071 Granada, Spain; jlllopis@ugr.es (J.L.); lorenrivas_lrg@hotmail.com (L.R.-G.); crissg@ugr.es (C.S.-G.)
4 Department of Computer Languages and Systems, Universitat Jaume I, 12071 Castellón, Spain
* Correspondence: dolores.corella@uv.es; Tel.: +34-96-386-4800
† Both authors contributed equally to this work as last authors.

Received: 8 March 2020; Accepted: 6 April 2020; Published: 8 April 2020

Abstract: Several studies have shown that a low magnesium (Mg) intake in the diet is associated with greater cardiovascular risk and greater risk of diabetes. However, the results are not consistent in all populations. To minimize the biases derived from diet measurement, more objective biomarkers of magnesium status have been proposed. Although there is still no ideal biomarker for Mg, several studies have shown that plasma Mg concentrations could be a relatively acceptable biomarker for cardiovascular risk assessment. However, further studies are required to better characterize this marker in different populations. Our aim was to analyze the association between plasma Mg concentrations (measured through inductively coupled plasma mass spectrometry (ICP-MS)) and cardiovascular risk factors in individuals from a general Mediterranean population (aged 18–80 years). The influence of demographic and lifestyle variables, including adherence to the Mediterranean diet, on plasma Mg concentrations was analyzed. The mean Mg level of the population studied was 0.77 ± 0.08 mmol/L, the prevalence of hypomagnesemia (<0.70 mmol/L) being 18.6%. We did not find any statistically significant differences between plasma Mg concentrations and sex, age, tobacco smoking and total adherence to the Mediterranean diet (p > 0.05). We found a statistically significant association between plasma Mg concentrations and the prevalence of type-2 diabetes (0.77 ± 0.08 mmol/L in non-diabetics versus 0.73 ± 0.13 mmol/L in diabetics; p = 0.009). Despite the low prevalence of type-2 diabetes in this population (11.24% in subjects with hypomagnesemia versus 3.91%, in normomagnesemia; p = 0.005), hypomagnesemia was associated with greater odds of being diabetic in comparison with normomagnesemia (OR = 3.36; p = 0.016, even after adjustment for sex, age, obesity, and medications). On the other hand, no statistically significant association of plasma Mg concentrations with obesity, hypertension, fasting triglycerides, HDL-cholesterol or uric acid was found. However, in contrast to what was initially expected, a statistically significant association was found between plasma Mg concentrations (basically in the highest quartile) and greater total cholesterol (p < 0.05) and LDL-cholesterol concentrations (p < 0.05). In conclusion, our results contribute to increasing the evidence gathered by numerous studies on the inverse association between hypomagnesemia and type-2 diabetes, as well as to the observation, previously
reported in some studies, of a direct association with hypercholesterolemia. This paradoxical link should be deeply investigated in further studies.

Keywords: magnesium; diabetes; cholesterol; mediterranean diet; mediterranean population

1. Introduction

Magnesium is considered as an essential mineral for the functioning of the organism, participating in approximately 80% of known metabolic functions [1] and playing both structural and regulatory roles in the organism [1,2]. It has been estimated that it is the fourth most abundant cation in the whole body and the second at the intracellular level [3,4]. Magnesium is an essential co-factor in the enzymatic pathways involved with energy, protein and lipid metabolism and the modulation of glucose transport through the cellular membrane [5–8]. Thus, magnesium serves as an important link between transport systems and metabolism, and its concentration in the cytoplasm is regulated in a highly precise manner [9–11]. Despite the importance of magnesium in the organism, there are various studies that indicate that a considerable percentage of the population may have magnesium intake lower than the optimum [12–14]. Thus, it has been estimated that 40%–50% of adults do not achieve the average dietary intake (ADI) [14–16]. Although it is problematic to find good indicators of so-called magnesium deficiency in organisms [14,17–20], a number of studies have been undertaken to reveal the percentage of the population that presents hypomagnesemia and its negative repercussions on health [20–23]. Many studies carried out on various populations have generally supported the protective role that magnesium plays when faced with different human health problems [22–26]. Thus, it is no surprise to find recommendations of increasing the consumption of magnesium to improve health. The scientific evidence backing up that recommendation is based on various randomized clinical trials in which magnesium supplements have been shown to improve several of the parameters analyzed, including plasma lipids, glycemic control, blood pressure, metabolic syndrome, inflammatory markers and endothelial function [27–33], among others. However, there are also other intervention studies that have detected no such improvements [34–37]. Although intervention studies with Mg supplements and under controlled experimental conditions may provide a high level of scientific evidence, these studies also have limitations related with small sample size and special population characteristics, and so it is necessary to obtain additional evidence from other studies, even though they be of an observational nature. Among those observational studies, much research has been undertaken on whether there exists a relationship between magnesium contribution through dietary food and different cardiovascular risk factors, diabetes and cardiovascular diseases [38]. Thus, some studies have reported inverse associations between dietary magnesium intake and body mass index (BMI) or obesity [39,40], blood pressure [40,41], total cholesterol/LDL-cholesterol concentrations [42], and fasting glucose or type-2 diabetes [41,43,44], but the overall consistency for some of these factors is still low. Regarding the incidence of cardiovascular diseases, some studies have reported that high magnesium intake is associated with a lower risk of stroke, heart failure and total cardiovascular events [45,46], but less agreement has been observed for other cardiovascular events [38,47]. Given the undoubted limitations to assessing the amount of magnesium intake through dietary foods, due to several biases derived from the use of food frequency questionnaires, the use of magnesium intake/status biomarkers is preferred as a more objective measure. Although there are still no perfect magnesium intake/status biomarkers [15,47–49], plasma/serum magnesium concentrations are the most widely practiced and accepted method of determining magnesium status in epidemiological studies [15,17,19], having more advantages than urinary magnesium concentrations that are more dependent on kidney function [50].

Several prospective cohort studies have analyzed plasma magnesium concentrations and cardiovascular disease incidence and diabetes risk, and some of them reported inverse associations in a meta-analysis [51]. Although at the cross-sectional level numerous researchers have investigated
associations between plasma magnesium concentrations and cardiovascular risk factors including plasma lipids, blood pressure, fasting glucose/diabetes, inflammation markers, among others, the consistency (except for type-2 diabetes), is still low [14,52–58]. Therefore, further studies are required on different populations in order to better understand those associations as well as the demographic and lifestyle factors associated with plasma magnesium concentrations. Hence, the objectives of our study were as follows: (1) to analyze plasma magnesium concentrations in a Mediterranean population and to investigate the influence of sex, age, urinary magnesium, tobacco smoking and adherence to the Mediterranean diet on those concentrations; and (2) to study the association between plasma magnesium concentrations and various cardiovascular risk phenotypes including body mass index (BMI), waist circumference, blood pressure, plasma lipid concentrations, fasting plasma glucose, type-2 diabetes, plasma creatinine, uric acid and aspartate aminotransferase in this population.

2. Materials and Methods

2.1. Study Design and Participants

We have carried out a cross-sectional analysis on 492 Caucasian subjects participating in the OBENUTIC-Mineral study. OBENUTIC stands for Obesity, Nutrition and Information and Communication Technologies and it is a case-control study conducted in the general population of the Valencia Region, Spain [59]. The ages of the participants in the OBENUTIC study were between 18 and 80 years old and included both men and women. Cases were obese subjects (body mass index (BMI) ≥ 30 kg/m²) and the controls were non-obese individuals (BMI < 30 kg/m²) recruited from the same region, without pairing for age and sex. The exclusion criteria were being pregnant or breast-feeding, invalidating physical or psychological diseases, cancer diagnosis, thyroid alterations, Cushing disease, suffering from some type of infectious/contagious disease, high alcohol intake or the consumption of other drugs. From participants in the OBENUTIC study, carried out over several years and with a greater sample size, a sub-set of 500 individuals recruited consecutively over 22 months was pre-selected for the OBENUTIC-Mineral sub-study. Of those, biological samples were obtained from 492 individuals in enough quantity to carry out the mineral determinations. In this particular study, focusing on measuring plasma magnesium concentrations as the main variable, 8 plasma samples with extreme values that deviate from other observations on data were detected, so indicating potential measurement errors or other types of incidence in the handling or conservation of the samples. These were considered as outliers, and the 8 individuals whose samples presented these outliers for magnesium concentrations were excluded from the study. Hence, in this work, 484 participants were finally included in the statistical analyses (160 men and 324 women), aged between 18 and 80 years old. Participants were apparently healthy individuals recruited through advertisements in shopping malls, housewives’ associations, cultural associations and other types of groups from the general population, public and private institutions, educational centers, some primary health care centers and home contacts. The study was undertaken at the Department of Preventive Medicine and Public Health, School of Medicine at the University of Valencia, Valencia. Participants provided written informed consent and study protocol and procedures were approved according to the ethical standards of the Helsinki Declaration and by the Human Research Ethics Committee of the University of Valencia, Valencia (reference number: H1488282121722).

2.2. Demographic, Anthropometric, Biochemical, Clinical and Lifestyle Variables

Socio-demographic, clinical variables (personal and family history of disease), medication use and lifestyle variables (smoking, physical activity, etc.) were obtained through a standardized questionnaire previously used in our studies [60]. Participants were measured for height with a standard stadiometer incorporated into the scales (SECA Mod 220, Seca Deutschland Gmbh and Co. Kg., Hamburg, Germany). Weight was determined with calibrated scales (TANITA-BC-420-S, Tanita UK Ltd., Middlesex, UK) [59]. Body Mass Index (BMI) was calculated as the weight in kilograms divided by the square of height in
meters. Obesity was defined as having a BMI ≥ 30 kg/m². Waist circumference was measured midway between the lowest rib and the iliac crest using an anthropometric tape. Waist circumference was considered high when ≥ 102 cm in men or ≥ 88 cm in women. Systolic and diastolic blood pressures were obtained using an automatic sphygmomanometer (Omron HEM-705CP, OMRON Healthcare Europe B.V., Hoofddorp, The Netherlands). Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or if subjects were receiving antihypertensive medication. Blood samples were collected after a 12-hour overnight fast. Plasma samples were obtained by centrifugation and the standard biochemical analyses were carried out the same day. In addition, plasma samples were stored at −80 °C for later analyses (i.e., magnesium determinations). Fasting plasma glucose, total cholesterol, HDL-cholesterol and triglyceride concentrations were measured using standard enzymatic methods as previously described [59] and LDL-cholesterol was estimated by the Friedewald equation (Olympus AU5400, Beckman Coulter, California, USA). Plasma creatinine was measured by the Jaffé method; uric acid was measured by the uricase method; and aspartate aminotransferase was measured by a standard method implemented on a Roche Diagnostics (Basel, Switzerland) multi-autoanalyzer in the same certified clinical laboratory. Diabetes was defined as having a fasting glucose ≥ 126 mg/dL or drug treatment for diabetes). Hypercholesterolemia was defined as LDL ≥ 160 mg/dL or taking lipid-lowering drugs. In addition, a first voided sample of urine, obtained the same day of the blood sample, was collected and stored at −80 °C for later analyses.

The level of adherence to the Mediterranean diet was measured by a validated 14-item questionnaire [61]. Registered dietitians completed the validated 14-item Mediterranean diet adherence screener (Supplemental Table S1) in a face-to-face interview with the participant. Each item was scored 0 or 1. The value of adherence to the Mediterranean diet was calculated as the summation of the 14 questions. A total score of 14 points indicates maximum adherence to the Mediterranean diet, whereas zero points indicates no adherence. For the total Mediterranean diet score, the greater the score, the greater the adherence. This variable was used as continuous and was also categorized for the statistical analyses. Subjects were classified as having low Mediterranean diet adherence (less than 9 points) or high adherence (≥ 9 points), based on the population mean of a previous study in our Mediterranean population [61]. For physical activity, sedentary status was defined as the auto-reported walking of less than 20 min a day. According to the World Health Organization, a current smoker was considered as someone who smokes any tobacco product at least once a day. Non-smokers included never and former smokers) [59].

2.3. Magnesium Determinations

Plasma magnesium was determined using an inductively coupled plasma mass spectrometer (ICP-MS) model 7500 supplied by Agilent Technologies (Agilent, Tokyo, Japan), using a carrier gas flow of 1.03 L/min, collision gas (He) flow of 4.3 mL/min, RF power of 1550 W and energy discrimination of 3 V, as previously reported [62]. All lenses were optimized daily. All materials used in the analyses were previously cleaned with supra-pure nitric acid and ultra-pure water (18.2 Ω) obtained using a Milli Q system. Samples and the certified reference material (Seronorm Trace Elements Serum L-1, Billingstad, Norway) were prepared by attack with nitric acid and hydrogen peroxide (supra-pure quality, Merck, Germany) in a microwave digester (Milestone, Sorisole, Italy). When the samples had been digested, the extracts were collected and made up to a final volume of 10 mL with-ultra pure water for subsequent analysis. The calibration curve was prepared following the Ga addition technique (adding 0.04 mg/L) as an internal standard, using stock solutions of 1000 mg/L of magnesium (Merck, Germany). The accuracy of the method was evaluated by analysis of the certified reference material, obtaining the value of 8.2 ± 0.2 μg/L (certified value 7.8–8.8 μg/L), and by recovery studies, obtaining a recovery of 93%. The mean of five separate determinations was used. For assessing the magnesium in urine, first morning urine samples were collected as previously indicated. Urine was not collected over 24 hours as recommended for the preferred method of urinary magnesium excretion determination [63], given that the urine samples in our study were already obtained and stored. Urine
samples were prepared with an acidic solution containing 1% NHO3 and 0.5% HCl. The determination of magnesium total content in urine samples was also performed by means of an ICP-MS instrument provided of a He collision cell. Calibration curves were prepared using Ga as an internal standard and by the dilution of stock solutions of 1.000 mg/L in 1% HNO3 (all reagents were supra-pure from Merck, Germany). The accuracy of this method for urine was evaluated by comparison with certified reference materials Seronorm™ Trace Elements Urine (Billingstad, Norway) and by recovery studies of spiked samples with multi-element standards. The calculated recovery was between 95% and 105% in all cases. The mean of separate determinations was used.

2.4. Statistical Analysis

Firstly, it was checked whether the continuous variables followed normal distribution to detect any outliers. For plasma magnesium concentrations, 8 outliers were detected in the 492 initially included participants. So that those values would not influence the later statistical analyses, it was decided to exclude those 8 individuals with those extreme determinations, and the analyses were then undertaken on the remaining 484 participants. The triglyceride variable in plasma was logarithmically transformed for statistical testing. Descriptive statistics were used to analyze the variables for socio-demographic, clinical and anthropometric data. Chi-squared tests were used to compare proportions. The t-test and ANOVA were used to compare crude means of continuous variables. Multivariate adjustments for comparisons of continuous variables were carried out by generalized linear models for continuous variables and multivariate logistic regression used for dichotomous variables. In addition to its use as a continuous variable, plasma magnesium was also used as a categorical variable. Four groups were created considering the population quartiles (Q) as follows: Q1 from 0.47 to 0.71 (mmol/L), Q2 from 0.72 to 0.77 (mmol/L), Q3 from 0.78 to 0.83 (mmol/L) and Q4 from 0.84 to 1.13 (mmol/L). Overall quartiles were used rather than sex-specific quartiles because no differences between sexes in plasma magnesium concentrations were detected. For the quartile analyses, p values for trend were calculated using the quartile median values. The age variable used as continuous was also categorized, taking the tertiles of the population into account. Multivariable logistic regression methods were used to estimate the odds ratios (OR) and the 95% confidence intervals (CI) associated with the corresponding risks as indicated. For both continuous and dichotomous variables, several models were used for estimating the sequential adjustment as follows: Model 1, unadjusted model; Model 2, model adjusted for age, sex and obesity; Model 3, model adjusted for age, sex, obesity, diabetes and medications (lipid-lowering drugs, antidiabetic drugs or antihypertensive drugs). Additional adjustments (also including the tests for interaction terms with sex or with obesity status in the corresponding regression models) were carried out for specific analysis and were indicated in the text. Analyses were mainly undertaken on the whole sample studied and stratified by sex or obesity when indicated. For urine magnesium analysis, 4 outliers were detected and removed from the presented statistical results. Even after the removal of the outliers, urine magnesium did not reach a normal distribution and a square root transformation for this variable was carried out. Data were analyzed using SPSS Statistics for Windows Ver. 26 (IBM Corp., Armonk, NY, USA). All tests were two-tailed and P-values <0.05 were considered statistically significant.

3. Results

3.1. Characteristics of the Population and Plasma and Urine Magnesium Concentrations

Table 1 shows the general characteristics of the studied population. The mean age was 46.28 ± 13.73 years, with no statistically significant differences between men and women (p = 0.520). The prevalence of obesity cases was 32%, being slightly higher in men than in women (p = 0.021). The prevalence of type-2 diabetes in this general population was low (5.41%), being higher in men (8.50%) than in women (3.88%); p = 0.039. Mean plasma magnesium in this population was 0.77 ± 0.08 mmol/L and no statistically significant differences between men and women were observed. Hypomagnesemia, defined
as having plasma magnesium concentrations < 0.70 mmol/L [64], was 18.6% in the whole population. No statistically significant differences in the prevalence of hypomagnesemia between men (17.5%) and women (19.1%) were detected ($p = 0.663$). Under normal conditions, plasma magnesium levels range from 0.66 to 1.05 mmol/L and are influenced by the balance between intestinal absorption and renal excretion [65]. In this sample, no subject was detected that presented hypermagnesemia. In addition to plasma magnesium, urinary magnesium was analyzed in a first morning urine sample and expressed it as mmol/L. Urine was not collected over 24 hours. Therefore, urinary magnesium in 24-hour urine was not calculated, even though this marker is preferred [63]. Thus, urine magnesium concentration was only used as a descriptive marker in this work and its association with cardiovascular risk factors was not analyzed. There are several works showing a good correlation between magnesium concentrations in the early morning urine sample and magnesium in the 24-hour urine collection method [66,67]. Some authors, however, have indicated that the early morning urine sample and the 24-hour urine collection cannot be used interchangeably in the evaluation of urinary magnesium excretion, as a good correlation does not translate into an agreement between the two measurements [68]. In the whole population, the mean urine magnesium concentration was 3.95 ± 2.17 mmol/L. Statistically significant differences were found between men and women (4.24 ± 2.13 mmol/L versus 3.81 ± 2.18 mmol/L, respectively; $p = 0.045$). This difference remained statistically significant even after multivariate adjustment for age, obesity, diabetes and medications ($p = 0.030$). Likewise, urinary magnesium concentrations were statistically different by age ($p < 0.001$), being lower in the older age group (Supplemental Figure S1). The correlation between plasma and urine magnesium (square root transformation for normality) concentrations was analyzed in the whole population and a direct statistically significant association ($r = 0.150$; $p = 0.001$) was found. As expected, despite being statistically significant, the magnitude of this correlation is low.

### Table 1. Demographic, anthropometric, clinical and biochemical characteristics of the participants by sex.

|                                | Total (n = 484) | Men (n = 160) | Women (n = 324) | $p$   |
|--------------------------------|-----------------|---------------|-----------------|-------|
| Age (years)                    | 46.28 ± 13.73   | 45.69 ± 14.75 | 46.58 ± 13.21   | 0.520 |
| BMI (Kg/m²)                    | 27.87 ± 5.44    | 29.17 ± 4.92  | 27.23 ± 5.58    | <0.001|
| SBP (mm Hg)                    | 124.81 ± 17.32  | 132.70 ± 15.88| 120.90 ± 16.67  | <0.001|
| DBP (mm Hg)                    | 78.52 ± 10.87   | 82.38 ± 12.11 | 76.60 ± 9.66    | <0.001|
| Total cholesterol (mg/dL)      | 211.94 ± 40.43  | 204.78 ± 38.86| 215.47 ± 40.78  | 0.006 |
| LDL-cholesterol (mg/dL)        | 137.82 ± 32.71  | 137.22 ± 32.21| 138.10 ± 32.99  | 0.781 |
| HDL-cholesterol (mg/dL)        | 59.65 ± 14.13   | 50.89 ± 11.03 | 63.94 ± 13.50   | <0.001|
| Triglycerides (mg/dL)          | 108.68 ± 58.15  | 122.55 ± 66.79| 101.85 ± 52.16  | <0.001|
| Fasting glucose (mg/dL)        | 94.91 ± 19.57   | 99.07 ± 23.08 | 92.87 ± 17.25   | 0.003 |
| Creatinine, mg/dL              | 0.76 ± 0.18     | 0.94 ± 0.19   | 0.10 ± 0.01     | <0.001|
| Uric acid, mg/dL               | 5.31 ± 1.42     | 1.24 ± 0.10   | 1.16 ± 0.06     | <0.001|
| Aspartate aminotransferase, U/L | 25.31 ± 10.44   | 29.77 ± 1.13  | 23.11 ± 7.00    | <0.001|
| Urine magnesium, mmol/L        | 3.95 ± 2.17     | 4.24 ± 2.13   | 3.81 ± 2.18     | 0.045 |
| Plasma magnesium, mmol/L       | 0.77 ± 0.08     | 0.78 ± 0.07   | 0.77 ± 0.08     | 0.106 |
| Hypomagnesemia %               | 18.6            | 17.5          | 19.1            | 0.663 |
| Obesity cases %                | 32.0            | 39.6          | 28.2            | 0.012 |
| Type 2 diabetes: %             | 5.41            | 8.50          | 3.88            | 0.039 |
| Hypercholesterolemia %         | 35.7            | 39.9          | 33.6            | 0.186 |
| Hypertension %                 | 31.9            | 48.4          | 23.6            | <0.001|
| Current smokers: %             | 20.1            | 16.2          | 21.9            | 0.118 |
| Antidiabetic drugs %           | 3.25            | 4.67          | 2.57            | 0.235 |
| Hypolipidemic drugs %          | 14.5            | 19.3          | 12.1            | 0.040 |
| Antihypertensive drugs %       | 16.9            | 28.7          | 11.2            | <0.001|

Values are mean ± SE for continuous variables and % for categorical variables. BMI indicates body mass index; SBP indicates systolic blood pressure, DBP indicates diastolic blood pressure; $p$: $p$-value for the comparisons (means or %) between men and women; hypomagnesemia: Plasma magnesium < 0.70 mmol/L; obesity: BMI ≥ 30 kg/m²; type 2 diabetes: Antidiabetic drug or glucose ≥ 126 mg/dL; hypercholesterolemia: Hypolipidemic drugs or LDL-cholesterol ≥ 160 mg/dL. hypertension: antihypertensive drug or PAS ≥ 140 mmHg or PAD ≥ 90 mmHg.
3.2. Association between Plasma Magnesium Concentrations and Demographic and Lifestyle Variables

Table 2 shows mean plasma magnesium concentrations depending on sex, age groups, tobacco smoking, sedentary lifestyle and adherence to Mediterranean diet. \( P \)-values are presented unadjusted and sequentially adjusted for the indicated potential confounders. In Model 3, men tended to have higher plasma magnesium concentrations than women, but differences did not reach statistical significance \( (p \text{ for Model 3: 0.059}) \). No significant differences were found in plasma magnesium concentrations by age group. Likewise, plasma magnesium concentrations did not differ by smoking status, sedentarism, or adherence to the Mediterranean diet \( (p > 0.05 \text{ for all}) \). In Table 2, adherence to the Mediterranean diet was considered as a categorical variable (high adherence versus low adherence based on the previously established cut-off point of nine points). Even after adjustment for sex, age, obesity, diabetes and medications, mean plasma magnesium values were similar in subjects with a high adherence \( (0.77 \pm 0.08 \text{ mmol/L in the low adherence level versus 0.77 \pm 0.08 mmol/L in the high adherence; } p = 0.665) \). Likewise, when adherence to Mediterranean diet was considered as a continuous variable, no statistically significant association with plasma magnesium levels was detected \( (p = 0.0728) \).

### Table 2. Associations between plasma magnesium concentrations and socio-demographic and lifestyle variables in the whole population.

| Variables                        | Categories            | Magnesium (mmol/L) | \( p^1 \)  | \( p^2 \)  | \( p^3 \)  |
|---------------------------------|-----------------------|--------------------|-----------|-----------|-----------|
| Sex                             | Men 0.78 ± 0.07       | 0.128              | 0.112     | 0.059     |
|| Women 0.77 ± 0.08              |                       |                    |           |           |
| Age                             | 18–42 years 0.77 ± 0.07 | 0.780              | 0.633     | 0.360     |
|| 43–54 years 0.77 ± 0.08        |                       |                    |           |           |
|| 55–80 years 0.77 ± 0.09        |                       |                    |           |           |
| Smoking                         | Non-smokers 0.77 ± 0.08 | 0.591              | 0.645     | 0.510     |
|| Current smokers 0.77 ± 0.08    |                       |                    |           |           |
| Sedentarism                      | No sedentarism 0.76 ± 0.08 | 0.153              | 0.183     | 0.131     |
|| Sedentarism 0.78 ± 0.08        |                       |                    |           |           |
| Adherence to Mediterranean diet  | Low-adherence 0.77 ± 0.08 | 0.643              | 0.788     | 0.644     |
|| High-adherence 0.77 ± 0.08     |                       |                    |           |           |

Variables are expressed as mean (± SD); \( p \): \( P \)-value for the comparisons (means) between levels of the different categories; \( ^1 \): \( P \)-value for the Model 1 (unadjusted); \( ^2 \): \( P \)-value for Model 2 (adjusted for sex, age and obesity); \( ^3 \): \( P \)-value for Model 3 (Model 2 additionally adjusted for diabetes and medications). A total of 484 subjects were analyzed for the comparisons.

However, when the specific foods of the Mediterranean diet were analyzed (Supplemental Table S2), some statistically significant differences were detected. Interestingly, two of the items related to olive oil consumption presented statistically significant associations with plasma magnesium concentrations. Individuals indicating the use of olive oil as the principal source of fat for cooking had a mean concentration of plasma magnesium of 0.77 ± 0.08 mmol/L versus 0.74 ± 0.07 mmol/L in subjects not using olive oil as the main fat. Likewise, an affirmative response to the second item (“use of 4 or more tablespoons of olive oil/d”) was also associated with higher plasma magnesium concentrations 0.78 ± 0.08 mmol/L versus 0.75 ± 0.08 mmol/L, in non-consumers; \( p = 0.012 \). These results remain statistically significant even after additional multivariate adjustment for age, sex, obesity, diabetes and medications. No statistically significant associations were detected for the other items.

3.3. Associations between Plasma Magnesium and Cardiovascular Risk Factors

The association between plasma magnesium concentrations and cardiovascular risk factors were then analyzed. Table 3 shows the results for anthropometric and clinical variables. No statistically
significant associations were observed for waist circumference, or obesity categories. Conversely, statistically significant associations were identified with type-2 diabetes and hypercholesterolemia. Plasma magnesium concentrations were lower in type-2 diabetic subjects in comparison with non-diabetic subjects (0.73 ± 0.13 mmol/L vs. 0.77 ± 0.08 mmol/L; p = 0.006 in a model adjusted for sex, age, obesity, diabetes and medications). Concerning hypercholesterolemia, a statistically significant association was also detected, but plasma magnesium concentrations were higher in hypercholesteremic subjects compared to non-hypercholesteremic (0.79 ± 0.09 mmol/L versus 0.76 ± 0.07 mmol/L; p = 0.001 in a multivariate model adjusted for sex, age, obesity, diabetes and medications).

Table 3. Associations between plasma magnesium concentrations and anthropometric and clinical variables in the whole population.

| Variables                          | Categories       | Magnesium (mmol/L) | p 1   | p 2   | p 3   |
|------------------------------------|------------------|--------------------|-------|-------|-------|
| Waist circumference, cm            | Low waist        | 0.77 ± 0.08        | 0.677 | 0.484 | 0.627 |
|                                    | High waist       | 0.77 ± 0.08        |       |       |       |
| BMI, kg/m²                         | Normal weight    | 0.76 ± 0.07        | 0.300 | 0.249 | 0.326 |
|                                    | Overweight       | 0.78 ± 0.08        |       |       |       |
|                                    | Obesity          | 0.77 ± 0.09        |       |       |       |
| Smoking                            | Non-smokers      | 0.77 ± 0.08        | 0.591 | 0.645 | 0.510 |
|                                    | Current smokers  | 0.77 ± 0.08        |       |       |       |
| Hypertension                       | No hypertension  | 0.77 ± 0.08        | 0.319 | 0.593 | 0.507 |
|                                    | Hypertension     | 0.78 ± 0.08        |       |       |       |
| Type-2 diabetes                    | No diabetes      | 0.77 ± 0.08        | 0.116 | 0.003 | 0.009 |
|                                    | Diabetes         | 0.73 ± 0.13        |       |       |       |
| Hypercholesterolemia               | No cholesterol   | 0.76 ± 0.07        | 0.002 | 0.004 | 0.001 |
|                                    | Hypercholesterolemia | 0.79 ± 0.09    |       |       |       |

Variables are expressed as mean (± SD); p: P-value for the comparisons (means) between categories of the different variables analyzed; \(^1\): P-value for Model 1 (unadjusted); \(^2\): P-value for Model 2 (adjusted for sex, age and obesity); \(^3\): P-value for Model 3 (Model 2 additionally adjusted for diabetes and medication where appropriate). Waist circumference was considered high when ≥ 102 cm in men or ≥ 88 cm in women. Normal weight: BMI < 25 kg/m²; overweight: BMI ≥ 25 kg/m² and BMI < 30 kg/m²; obesity: BMI ≥ 30 kg/m²; type-2 diabetes: use of antidiabetic drugs and/or fasting glucose ≥ 126 mg/dl; hypercholesterolemia: use of lipid lowering drugs and/or plasma LDL-cholesterol ≥ 160 mg/dl. hypertension: antihypertensive drugs or PAS ≥ 140 mmHg or PAD ≥ 90 mmHg.

The relationship between hypomagnesemia (plasma magnesium < 0.70 mmol/L) and prevalence of diabetes (Table 4) was then examined. The prevalence of type-2 diabetes was 11.24% in subjects with hypomagnesemia and 3.11% in subjects with normomagnesemia. Hypomagnesemia was higher in type-2 diabetic subjects in comparison to non-diabetics (40.0% versus 17.4%; p = 0.008, respectively). In the multivariate adjusted Model 3, the odds of being type-2 diabetic in subjects with hypomagnesemia was high, OR: 3.36 (95% CI: 1.26–8.96); p = 0.016.

Table 4. Association between hypomagnesemia\(^1\) and prevalence of type-2 diabetes.

| Mg                  | Non T2D (%) | T2D (%) | Model 1 OR (95% CI) \(^1\) P | Model 2 OR (95% CI) \(^2\) P | Model 3 OR (95% CI) \(^3\) P |
|---------------------|-------------|---------|------------------------------|-----------------------------|-----------------------------|
| Normomagnesemia     | 96.09       | 3.91    | 1.00 (reference)             | 1.00 (reference)            | 1.00 (reference)            |
| Hypomagnesemia      | 88.76       | 11.24   | 3.11 (1.35–7.19) 0.008       | 3.01 (1.22–7.42) 0.017       | 3.36 (1.26–8.96) 0.016       |

\(^1\): Hypomagnesemia was considered when plasma magnesium < 0.70 mmol/L. OR: odds ratio; CI: confidence interval. T2D: type-2 diabetes. Multivariate logistic regression analysis: Model 1: unadjusted model; Model 2: adjusted for sex, age and obesity; Model 3: adjusted for sex, age, obesity and medications.
However, hypomagnesemia was not statistically related to hypercholesterolemia. In the multivariate logistic regression model adjusted for sex, age, obesity, diabetes and medications, the odds for hypercholesterolemia did not reach statistical significance (OR: 1.38; 95%CI: 0.81–2.35; \( p = 0.233 \)). To better understand the dose–response relationship between plasma magnesium and cholesterol as well as with the other cardiovascular risk factors, quartiles of plasma magnesium were created and the association between these quartiles and the corresponding cardiovascular risk variables was studied (Table 5).

### Table 5. Association between the plasma magnesium quartiles (Q) and plasma lipids, fasting glucose, creatinine, uric acid and aspartate aminotransferase in the whole population.

|                | Q1 (0.47–0.71 mmol/L) | Q2 (0.72–0.77 mmol/L) | Q3 (0.78–0.83 mmol/L) | Q4 (0.84–1.13 mmol/L) | \( p^1 \) | \( p^2 \) | \( p^3 \) |
|----------------|------------------------|-----------------------|-----------------------|-----------------------|---------|---------|---------|
| \( n \)        | 121                    | 122                   | 121                   | 120                   |         |         |         |
| SBP, mmHg      | 124.06 ± 17.68         | 123.22 ± 17.75        | 124.79 ± 17.87        | 127.22 ± 15.83        | 0.314   | 0.692   | 0.656   |
| DBP, mmHg      | 77.25 ± 11.97          | 78.81 ± 10.60         | 78.49 ± 11.10         | 79.54 ± 9.70          | 0.428   | 0.505   | 0.331   |
| Total-cholesterol, mg/dL | 206.85 ± 35.63       | 210.20 ± 39.25        | 208.88 ± 41.09        | 221.91 ± 44.09        | 0.017   | 0.010   | 0.010   |
| LDL-cholesterol, mg/dL | 132.60 ± 28.89       | 135.51 ± 32.10        | 136.17 ± 32.39        | 147.05 ± 35.66        | 0.003   | 0.004   | 0.002   |
| HDL-cholesterol, mg/dL | 59.26 ± 14.80        | 60.48 ± 14.11         | 59.53 ± 14.26         | 59.32 ± 13.46         | 0.901   | 0.781   | 0.933   |
| Triglycerides, mg/dL | 110.36 ± 56.26        | 106.12 ± 52.57        | 105.53 ± 62.68        | 112.79 ± 61.00        | 0.570   | 0.800   | 0.959   |
| Glucose, mg/dL  | 99.93 ± 29.66          | 91.66 ± 13.86         | 94.49 ± 13.50         | 93.62 ± 15.80         | 0.007   | 0.003   | 0.223   |
| Creatinine, mg/dL | 0.74 ± 0.14           | 0.736 ± 0.17          | 0.80 ± 0.24           | 0.770±0.16             | 0.030   | 0.049   | 0.032   |
| Uric acid, mg/dL | 5.22 ± 1.42           | 5.24 ± 1.38           | 5.34 ± 1.58           | 5.43 ± 1.32           | 0.625   | 0.986   | 0.982   |
| Aspartate aminotransferase, U/L | 24.49 ± 9.92        | 25.26±11.08           | 25.57 ± 10.13         | 25.89 ± 10.64         | 0.801   | 0.944   | 0.873   |

Values are mean±SD for continuous variables. SBP indicates systolic blood pressure. DBP indicates diastolic blood pressure; \( p^1 \): \( p \)-value for trend across quartiles for the comparisons (means); \( p^2 \): \( p \)-value for Model 1 (unadjusted); \( p^3 \): \( p \)-value for Model 2 (adjusted for sex, age and obesity); \( p^4 \): \( p \)-value for Model 3 (Model 2 additionally adjusted for diabetes and medications (lipid-lowering, antihypertensive drugs, antidiabetic drugs) when appropriate).

Plasma magnesium was not statistically associated with blood pressure, HDL-cholesterol, fasting triglycerides, uric acid or aspartate aminotransferase in this sample. In Model 3, however, statistically significant results for total cholesterol (\( p = 0.010 \) in Model 3) were observed as well as for LDL-cholesterol (\( p = 0.002 \) in Model 3). According to these results, higher plasma magnesium concentrations were directly related to higher total cholesterol and LDL-cholesterol, mainly in the fourth quartile. This result is contrary to the previously observed relationship with diabetes. Likewise, another statistically significant direct association was detected with creatinine levels (\( p = 0.032 \) in Model 3). As higher plasma creatinine is an indicator of altered renal function, additional adjustments were made for creatinine concentrations in Model 3 to better understand the association between plasma magnesium and total cholesterol and LDL-cholesterol. After this additional adjustment, both total cholesterol and LDL-cholesterol remained statistically associated with higher plasma magnesium levels.

When the influence of obesity on the magnesium effect on biochemical parameters was analyzed by estimating the statistical significance of the interaction term between obesity and magnesium in determining the corresponding cardiovascular risk factor, no statistically significant interaction terms were found for any of the variables analyzed in the multivariate adjusted models. The \( p \) values for the corresponding interaction terms were as follows: for fasting glucose: \( p = 0.467 \); for total cholesterol: \( p = 0.157 \); for LDL-cholesterol: \( p = 0.282 \); for HDL-cholesterol: \( p = 0.194 \); for triglycerides: \( p = 0.846 \); for creatinine: \( p = 0.549 \); for SBP: \( p = 0.592 \); and for diastolic blood pressure: \( p = 0.702 \) (not shown in tables). Likewise, heterogeneity per sex was analyzed for these parameters, but no statistically significant interaction term was observed. \( p = 0.412 \); for total cholesterol: \( p = 0.643 \); for LDL-cholesterol: \( p = 0.827 \).
for HDL-cholesterol: \( p = 0.152 \); for triglycerides: \( p = 0.675 \); for creatinine: \( p = 0.105 \); for SBP: \( p = 0.789 \); and for diastolic blood pressure: \( p = 0.424 \) (not shown in tables).

Finally, we estimated the odds for hypercholesterolemia depending on the quartiles of plasma magnesium (Table 6). Although a statistically significant linear trend was detected between plasma magnesium and hypercholesterolemia OR: 1.41; 95%CI: 1.12–1.76 per standard deviation; \( p = 0.003 \) (in Model 3), the association was mainly propelled by the fourth quartile of plasma magnesium. Thus, subjects with a high plasma magnesium level have higher odds of having hypercholesterolemia than subjects in the first magnesium quartile: OR: 3.12; 95%CI: 1.66–5.85; \( p < 0.001 \).

**Table 6.** Association between quartiles (Q) of plasma magnesium levels and the risk of hypercholesterolemia.

| Q    | No Hypercholesterolemia (%) | Hyper-Cholesterol (%) | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) |
|------|-----------------------------|-----------------------|---------------------|---------------------|---------------------|
| Q1   | 72.03                       | 27.97                 | 1.00 (reference)    | 1.00 (reference)    | 1.00 (reference)    |
| Q2   | 67.23                       | 32.77                 | 1.26 (0.72–2.19)    | 1.50 (0.80–2.80)    | 1.62 (0.85–3.10)    |
| Q3   | 68.07                       | 31.93                 | 1.21 (0.69–2.11)    | 1.27 (0.68–2.39)    | 1.44 (0.75–2.77)    |
| Q4   | 50.00                       | 50.00                 | 2.58 (1.50–4.42)    | 2.80 (1.52–5.16)    | 3.12 (1.66–5.85) |

| Linear effect | 1.36 (1.12–1.65) | 1.34 (1.08–1.66) | 1.41 (1.12–1.76) |

Q1: 0.47–0.71 mmol/L; Q2: 0.72–0.77 mmol/L; Q3: 0.78–0.83 mmol/L; Q4: 0.84–1.13 mmol/L. OR: odds ratio. CI: confidence interval. Multivariate logistic regression analysis: Model 1: unadjusted model; Model 2: adjusted for sex, age and obesity; Model 3: adjusted for sex, age, obesity, diabetes and medication. \(^1\) For the estimation of the additive effect of plasma magnesium, the variable was considered as continuous and was first standardized. Thus, the OR expressed the increase in the risk per standard deviation of plasma magnesium concentrations. \( p = 1.23 \); \( p \)-value obtained for the plasma magnesium variable in the corresponding multivariate logistic regression models.

4. Discussion

In this study, the prevalence of hypomagnesemia was found to be 18.6% [64]. Although in the literature there is heterogeneity in defining the cut-off point for hypomagnesemia, among the different critical values mentioned—0.8 mmol/L, 0.75 mmol/L, and 0.7 mmol/L [69]—the critical value of 0.7 mmol/L used in our study has been widely reported in several studies [25,64,70–73] but not in others. It has been stated that hypomagnesemia ranges from 2.0% to 15% in healthy subjects, and between 14% and 48% in type-2 diabetic subjects [25,64,74–77]. In addition to the different population characteristics, this wide range in the reported prevalence most likely reveals the difference in the criteria for the definition of hypomagnesemia as well as the differences in the techniques and samples (plasma/serum) used in magnesium measurements. The prevalence of hypomagnesemia in our study was very high in type-2 diabetic subjects (40.0%) in comparison with non-diabetic subjects (17.4%). Despite the small prevalence of type-2 diabetes in this population (5.41%), the association with hypomagnesemia reached statistical significance and was a relevant finding in our study. Although this is not a new finding considering that since the 1940s, type-2 diabetes has been reported to be associated with hypomagnesemia [78], it is important as, even in this scarcely studied Mediterranean population, we have been able to replicate previous findings on the strong association between low plasma levels of magnesium and diabetes risk [52,54,64,65]. Despite this strong association, there is currently little interest in hypomagnesemia, and plasma magnesium is not generally measured in large cohorts from the general population or even in patients at risk of type-2 diabetes. The relative lack of symptoms of hypomagnesemia until plasma concentrations reach severely low levels as well as the relatively poor understanding of magnesium metabolism may have contributed to this relatively low awareness for hypomagnesemia. Recently, another study carried out in the south of Spain in
patients with coronary heart disease recruited in the CORDIOPREV trial [53] also reported a strong cross-sectional association between serum magnesium concentration and the prevalence of type-2 diabetes. Moreover, in this study, serum magnesium was strongly and inversely associated with the Carotid Intima-Media Thickness, even after adjustment for diabetes. Despite the widespread clinical and epidemiological evidence of the association of hypomagnesemia and type-2 diabetes, it is not entirely clear if this association is the cause or a consequence. It has been reported that several drugs, including antidiabetic drugs and other drugs used for diabetes complications, are associated with low plasma magnesium [79–81] and can contribute to the hypomagnesemia observed in type-2 diabetic subjects. However, it has been estimated that only a minor part of hypomagnesemia can be explained by drug consumption [79]. Due to the cross-sectional nature of our study, more factors determining the low plasma magnesium in type-2 diabetic subjects could not be investigated. However, some cohort studies have prospectively analyzed the incidence of new cases of type-2 diabetes and have reported an inverse association with plasma magnesium concentrations [51,82–84], minimizing the cross-sectional bias. Thus, in a cohort of more than 12,000 nondiabetic subjects from the Atherosclerosis Risk in Communities Study during 6 years of follow-up [82], the authors detected an approximate two-fold statistically significant increase in incidence rate of type-2 diabetes comparing the highest to the lowest (categorized into 6 groups). Likewise, Guerrero-Romero at al. [83] analyzed the risk conferred by hypomagnesemia of new onset type-2 diabetes after 10 years of follow-up and estimated a relative risk (RR) of 2.5; (95%CI: 1.1–4.1). In a meta-analysis of the published cohort studies [51], the pooled RR for incidence of type-2 diabetes comparing the highest to the lowest category of magnesium concentrations was RR: 0.64; 95% CI: 0.50–0.81. Likewise, numerous cohort studies analyzing dietary magnesium intake also found a protective effect, though of less magnitude. Thus, in a meta-analysis including 25 cohorts [85] comprising more than 600,000 individuals (approx. 27,000 type-2 diabetics), the highest category of magnesium intake compared with the lowest, reduced the risk of type-2 diabetes across all the cohorts by 17%. Similarly, a meta-analysis of randomized controlled trials on the effects of magnesium supplementation on fasting glucose and insulin sensitivity [37] concluded that magnesium supplementation for more than 4 months significantly improved insulin resistance and fasting glucose in diabetic and in non-diabetic individuals. However, the mechanisms by which magnesium can improve insulin resistance and decrease diabetes risk are still far from understood [64].

Focusing on factors related to serum magnesium concentrations, no statistically significant differences were detected per sex, age, BMI, or smoking status in our population. These factors have been analyzed in various studies [15,53,55,63,77,86], obtaining different results depending on the population analyzed. Mataix et al. [15], in a study undertaken to identify factors influencing plasma magnesium levels in the general population of southern Spain, and in agreement with our results, did not observe any association between plasma levels of magnesium and sex, age, obesity, tobacco smoking, alcohol drinking, educational level or sedentarism. Also, in southern Spain, but analyzing subjects at high cardiovascular risk, Rodriguez-Ortiz at al. [33] detected statistically significant age differences, but no differences depending on sex, BMI or tobacco smoking. Conversely, Bertinato et al. [86], analyzing a representative population from Canada, described statistically significant differences in serum concentrations depending on the sex, age and BMI. Genetic factors [87,88] and/or dietary intake may modulate these associations and contribute to the differences among populations. Although there are several genetic polymorphisms in the transient receptor potential cation channel subfamily M member 6 (TRPM6) gene and in the ADP Ribosylation Factor Like GTPase 15 (ARL15) gene, among others [87,88] that have been related to magnesium levels, this analysis was not the focus of our study and their contribution in this populations remains to be investigated. Nevertheless, diet in this population at the dietary pattern level was analyzed. A validated questionnaire was used for measuring adherence to the Mediterranean diet pattern [61]. No statistically significant association was found between total adherence to the Mediterranean diet and plasma magnesium concentrations in this population. This observation was relatively expected because previous studies analyzing at the same time the correlation between total dietary magnesium intake, assessed by questionnaire, and plasma
magnesium concentrations did not observe significant associations [14,64,82,89,90]. One limitation of our study is that the amount of magnesium provided by dietary foods was not measured and so this direct measure was not available to evaluate the association between total magnesium intake and plasma magnesium concentration. We focused on the Mediterranean diet pattern because the number of studies analyzing the association between the Mediterranean diet pattern and plasma magnesium concentrations is very scarce. Using a different instrument for measuring the adherence to the Mediterranean diet [91], the Mediterranean diet quality index (Med-DQI), instead of our validated 14-item score for adherence [61], Bahreini et al. [91] in Iran measured Mediterranean diet adherence and observed a significant association with serum magnesium concentrations in 102 patients. Higher adherence to the Mediterranean diet was associated with higher magnesium concentrations. In our study, despite not observing a significant association with total adherence to the Mediterranean diet, significant associations were found with two items of the score related to the olive oil consumption. Hence, in our study, subjects who consumed olive oil as the main fat for cooking and had more than four spoonfuls a day had higher plasma magnesium concentrations. As this is the first time that this association has been reported, we cannot assess its plausibility or say whether this was by chance. It is possibly due to an indirect association with other factors, as olive oil per se does not contribute any significant concentrations of magnesium. It is known that magnesium deficiency causes inflammatory and oxidative stress [1,2] and that, in turn, the anti-inflammatory and anti-oxidizing effect of virgin olive oil could mimic the protective effect of plasma magnesium, contributing to the observed higher levels. Until now, no studies have been published on whether virgin olive oil may be associated with higher levels of plasma magnesium and despite the results obtained, we are aware of the small number of individuals in our study, so it will be necessary to undertake these analyses in populations with a greater number of participants.

Finally, another unexpected finding in our study is the direct association found between plasma magnesium and total cholesterol and LDL-cholesterol concentrations. This finding seems contradictory taking into account that high LDL-cholesterol has been associated with higher cardiovascular disease in several studies [92] and, on the other hand, there are several studies showing that higher plasma magnesium concentrations is associated with lower cardiovascular disease risk [38,51,93]. The results of studies that have analyzed the influence of magnesium supplementation on plasma lipid concentrations have been contradictory [37,93]. Thus, Shahbah et al. [94], in a clinical trial on children, reported improvements in the atherogenic lipid profile (decreases in total cholesterol and LDL-cholesterol after intervention with magnesium supplements). Other intervention studies reached the same conclusion in adults; however, a meta-analysis of randomized controlled trials on the effects of magnesium supplementation on lipid profile [37] concluded that no decrease in total cholesterol or LDL-cholesterol was observed in the pooled analysis. Likewise, in observational studies, the results regarding total cholesterol and LDL-cholesterol are inconclusive [38]. Some studies showed a statistically significant inverse association between plasma magnesium and total or LDL-cholesterol [95,96], but other studies did not observe any significant association [38,55,57,97]. Moreover, there are numerous publications [53,56,57,98,99], that, in agreement with our results, found statistically significant direct associations between plasma magnesium concentrations and total and/or LDL-cholesterol levels, but they did not emphasize the findings. If confirmed in later studies, these findings may help to explain inconsistent results in some studies analyzing plasma magnesium and cardiovascular risk due to the concomitant increase in the atherogenic LDL-cholesterol, but more research must be done on the potential mechanisms involved.

5. Conclusions

In this study, undertaken on individuals coming from a general Mediterranean population from the East Mediterranean coast of Spain, no differences in plasma magnesium concentrations were found according to sex, age, obesity or tobacco smoking. Nor was any association found between magnesemia and total adherence to the Mediterranean diet, but significant associations with olive oil consumption
were obtained, which require further investigation. No significant associations were found between plasma magnesium and blood pressure, plasma triglycerides, HDL-cholesterol, uric acid or aspartate aminotransferase. However, a statistically significant inverse association was confirmed between magnesemia and prevalence of type-2 diabetes, as previously reported in several studies reporting a protective role of plasma magnesium in this disease. Conversely, in agreement with some other cross-sectional studies, a direct association was detected between higher plasma magnesium and higher total cholesterol and LDL-cholesterol. This association is mainly observed in the highest quartile of magnesium concentrations. This result seems contradictory with studies that indicate a strong inverse association of plasma magnesium concentrations with lower cardiovascular risk and, therefore, more specific investigation in other studies is required.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2072-6643/12/4/1018/s1:
- Supplemental Table S1: Quantitative 14-item questionnaire for Adherence to Mediterranean diet; Supplemental Figure S1: Urinary magnesium concentration depending on the age group in the whole population; Supplemental Table S2: Mediterranean diet adherence components and plasma magnesium concentrations depending on the item analyzed.

**Author Contributions:** The authors’ responsibilities were as follows: R.B., O.P., J.V.S. and D.C. conceived and designed the study; R.B., E.M.A., C.O.-A., and O.P. recruited participants; R.B., E.M.A. and C.O.-A. obtained the data; L.R.-G. and C.S.-G.; determined metal concentrations; R.B., E.M.A., C.O.-A., J.V.S. and D.C. analyzed the data; R.B., O.C., and D.C. performed the statistical analyses; D.C., J.L., O.C., C.S.-G. and R.B. wrote the paper; J.L., C.S.-G., O.C., R.B. and D.C. critically evaluated the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was partially funded, by the Spanish Ministry of Health (Instituto de Salud Carlos III) and the Ministerio de Economía y Competitividad-Fondo Europeo de Desarrollo Regional (FEDER) (grants CIBER 06/03, SAF2016–80532-R); the Junta de Andalucía (AGRI15 research group); the University Jaume I (grant P1–1B2013–54); the Fundación La Marató de TV3 (grant 538/U/2016) and the Generalitat Valenciana (grants PROMETEO2017/017, and APOSTD/2019/136).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Volpe, S.L. Magnesium in disease prevention and overall health. *Adv. Nutr.* 2013, 4, 378S–383S. [CrossRef] [PubMed]
2. Shahi, A.; Aslani, S.; Ataollahi, M.; Mahmoudi, M. The role of magnesium in different inflammatory diseases. *Inflammopharmacology* 2019, 27, 649–661. [CrossRef] [PubMed]
3. Glasdam, S.-M.; Glasdam, S.; Peters, G.H. The Importance of Magnesium in the Human Body: A Systematic Literature Review. *Adv. Clin. Chem.* 2016, 73, 169–193. [PubMed]
4. Rashvand, S.; Mobasseri, M.; Tarighat-Esfanjani, A. Effects of Choline and Magnesium Concurrent Supplementation on Coagulation and Lipid Profile in Patients with Type 2 Diabetes Mellitus: A Pilot Clinical Trial. *Biol. Trace Elem. Res.* 2020, 194, 328–335. [CrossRef]
5. Guerrero-Romero, F.; Rodríguez-Morán, M. Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. *Diabetes Metab. Res. Rev.* 2006, 22, 471–476. [CrossRef]
6. Barbagallo, M.; Dominguez, L.J. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. *Arch. Biochem. Biophys.* 2007, 458, 40–47. [CrossRef]
7. Romani, A.M.P. Cellular magnesium homeostasis. *Arch. Biochem. Biophys.* 2011, 512, 1–23. [CrossRef]
8. Shafeeq, S.; Mahboob, T. Magnesium supplementation ameliorates toxic effects of 2,4-dichlorophenoxyacetic acid in rat model. *Hum. Exp. Toxicol.* 2020, 39, 47–58. [CrossRef]
9. Trapani, V.; Wolf, F.I. Mitochondrial magnesium to the rescue. *Magnes. Res.* 2015, 28, 79–84. [CrossRef]
10. Rubin, H. Magnesium: The missing element in molecular views of cell proliferation control. *Bioessays* 2005, 27, 311–320. [CrossRef]
11. Picone, G.; Cappadone, C.; Pasini, A.; Lovecchio, J.; Cortesi, M.; Farruggia, G.; Lombardo, M.; Gianoncelli, A.; Mancini, L.; Ralf H., M.; et al. Analysis of intracellular magnesium and mineral depositions during osteogenic commitment of 3d cultured saos2 cells. *Iffms* 2020, 21, 2368. [CrossRef]
12. Tarleton, E.K. Factors influencing magnesium consumption among adults in the United States. *Nutr. Rev.* 2018, 76, 526–538. [CrossRef] [PubMed]
13. Rosanoff, A.; Weaver, C.M.; Rude, R.K. Suboptimal magnesium status in the United States: Are the health consequences underestimated? *Nutr. Rev.* **2012**, *70*, 153–164. [CrossRef]

14. Mataix, J.; Aranda, P.; López-Jurado, M.; Sánchez, C.; Planells, E.; Llopis, J. Factors influencing the intake and plasma levels of calcium, phosphorus and magnesium in southern Spain. *Eur. J. Nutr.* **2006**, *45*, 349–354. [CrossRef] [PubMed]

15. Workinger, J.L.; Doyle, R.P.; Bortz, J. Challenges in the Diagnosis of Magnesium Status. *Nutrients* **2018**, *10*, 1202. [CrossRef] [PubMed]

16. Guo, W.; Hussain, N.; Liang, Z.; Yang, D. Magnesium deficiency in plants: An urgent problem. *J. Crop* **2016**, *4*, 83–91. [CrossRef]

17. Reddy, S.T.; Soman, S.S.; Yee, J. Magnesium Balance and Measurement. *Adv. Chronic Kidney Dis.* **2018**, *25*, 224–229. [CrossRef] [PubMed]

18. Veronese, N.; Zanforlini, B.M.; Manzato, E.; Sergi, G. Magnesium and healthy aging. *Magnes. Res.* **2015**, *28*, 112–115. [CrossRef]

19. Razzaque, M. Magnesium: Are We Consuming Enough? *Nutrients* **2018**, *10*, 1863. [CrossRef]

20. Nielsen, F.H. The Problematic Use of Dietary Reference Intakes to Assess Magnesium Status and Clinical Importance. *Biol. Trace Elem. Res.* **2019**, *188*, 52–59. [CrossRef]

21. Ismail, A.A.A.; Ismail, Y.; Ismail, A.A. Chronic magnesium deficiency and human disease; time for reappraisal? *QJM* **2018**, *111*, 759–763. [CrossRef]

22. Nielsen, F.H. Dietary Magnesium and Chronic Disease. *Adv. Chronic Kidney Dis.* **2018**, *25*, 230–235. [CrossRef]

23. Gant, C.M.; Soedamah-Muthu, S.S.; Binnenmars, S.H.; Bakker, S.J.L.; Navis, G.; Laverman, G.D. Higher Dietary Magnesium Intake and Higher Magnesium Status Are Associated with Lower Prevalence of Coronary Heart Disease in Patients with Type 2 Diabetes. *Nutrients* **2018**, *10*, 307. [CrossRef]

24. Kirkland, A.E.; Sarlo, G.L.; Holton, K.F. The Role of Magnesium in Neurological Disorders. *Nutrients* **2018**, *10*, 730. [CrossRef]

25. Gröber, U.; Schmidt, J.; Kisters, K. Magnesium in Prevention and Therapy. *Nutrients* **2015**, *7*, 8199–8226. [CrossRef]

26. Liu, M.; Yang, H.; Mao, Y. Magnesium and liver disease. *Ann. Transl. Med.* **2019**, *7*, 578. [CrossRef]

27. Marques, B.C.A.A.; Klein, M.R.S.T.; da Cunha, M.R.; de Souza Mattos, S.; de Paula Nogueira, L.; de Paula, T.; Corrêa, F.M.; Oigman, W.; Neves, M.F. Effects of Oral Magnesium Supplementation on Vascular Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *High Blood Press. Cardiovasc. Prev.* **2020**, *27*, 19–28. [CrossRef]

28. Rodriguez-Morán, M.; Simental-Mendia, L.E.; Gamboa-Gómez, C.I.; Guerrero-Romero, F. Oral Magnesium Supplementation and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial. *Adv. Chronic Kidney Dis.* **2018**, *25*, 261–266. [CrossRef]

29. Guerrero-Romero, F.; Jaquez-Chairez, F.O.; Rodríguez-Morán, M. Magnesium in metabolic syndrome: A review based on randomized, double-blind clinical trials. *Magnes. Res.* **2016**, *29*, 146–153. [CrossRef]

30. ELDerawi, W.A.; Naser, I.A.; Taleb, M.H.; Abutair, A.S. The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients. *Nutrients* **2018**, *11*, 44. [CrossRef]

31. Asemi, Z.; Karamali, M.; Jamilian, M.; Foroozanfard, F.; Bahmani, F.; Heidarzadeh, Z.; Benisi-Kohansal, S.; Surkan, P.I.; Esmaillzadeh, A. Magnesium supplementation affects metabolic status and pregnancy outcomes in gestational diabetes: A randomized, double-blind, placebo-controlled trial. *Am. J. Clin. Nutr.* **2015**, *102*, 222–229. [CrossRef] [PubMed]

32. Dibaba, D.T.; Xun, P.; Song, Y.; Rosanoff, A.; Shechter, M.; He, K. The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: A meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* **2017**, *106*, 921–929. [CrossRef] [PubMed]

33. Simental-Mendia, L.E.; Sahebkar, A.; Rodriguez-Morán, M.; Zambrano-Galvan, G.; Guerrero-Romero, F. Effect of Magnesium Supplementation on Plasma C-reactive Protein Concentrations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Curr. Pharm. Des.* **2017**, *23*, 4678–4686. [CrossRef]

34. Sadeghian, M.; Azadbakht, L.; Khalili, N.; Mortazavi, M.; Esmaillzadeh, A. Oral Magnesium Supplementation Improved Lipid Profile but Increased Insulin Resistance in Patients with Diabetic Nephropathy: A Double-Blind Randomized Controlled Clinical Trial. *Biol. Trace Elem. Res.* **2020**, *193*, 23–35. [CrossRef]
35. Bullarbo, M.; Mattson, H.; Broman, A.-K.; Ödman, N.; Nielsen, T.F. Magnesium Supplementation and Blood Pressure in Pregnancy: A Double-Blind Randomized Multicenter Study. *J. Pregnancy* **2018**, *2018*, 4843159. [CrossRef]

36. Dickinson, H.O.; Nicolson, D.J.; Campbell, F.; Cook, J.V.; Beyer, F.R.; Ford, G.A.; Mason, J. Magnesium supplementation for the management of essential hypertension in adults. *Cochrane Database Syst. Rev.* **2006**, CD004640. [CrossRef]

37. Simental-Mendia, L.E.; Simental-Mendia, M.; Sahebkar, A.; Rodriguez-Morán, M.; Guerrero-Romero, F. Effect of magnesium supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials. *Eur. J. Clin. Pharmacol.* **2017**, *73*, 525–536. [CrossRef]

38. Rosique-Esteban, N.; Guasch-Ferré, M.; Hernández-Alonso, P.; Salas-Salvadó, J. Dietary Magnesium and Cardiovascular Disease: A Review with Emphasis in Epidemiological Studies. *Nutrients* **2018**, *10*, 168. [CrossRef]

39. Lu, L.; Chen, C.; Yang, K.; Zhu, J.; Xun, P.; Shikany, J.M.; He, K. Magnesium intake is inversely associated with risk of obesity in a 30-year prospective follow-up study among American young adults. *Eur. J. Nutr.* **2020**, 1–9. [CrossRef]

40. McKeown, N.M.; Jacques, P.F.; Zhang, X.L.; Yuan, W.; Sahyoun, N.R. Dietary magnesium intake is related to metabolic syndrome in older Americans. *Eur. J. Nutr.* **2008**, *47*, 210–216. [CrossRef]

41. Chan, Q.; Stamler, J.; Gripp, L.M.O.; Daviglus, M.L.; Horn, L.V.; Elliott, P. An Update on Nutrients and Blood Pressure. *J. Atheroscler. Thromb.* **2016**, *23*, 276–289. [CrossRef]

42. Bain, L.K.M.; Myint, P.K.; Jennings, A.; Lentjes, M.A.H.; Luben, R.N.; Khaw, K.-T.; Wareham, N.J.; Welch, A.A. The relationship between dietary magnesium intake, stroke and its major risk factors, blood pressure and cholesterol, in the EPIC-Norfolk cohort. *Int. J. Cardiol.* **2015**, *196*, 108–114. [CrossRef] [PubMed]

43. Hruby, A.; Guasch-Ferré, M.; Bhupathiraju, S.N.; Manson, J.E.; Willett, W.C.; McKeown, N.M.; Hu, F.B. Magnesium Intake, Quality of Carbohydrates, and Risk of Type 2 Diabetes: Results From Three U.S. Cohorts. *Diabetes Care* **2017**, *40*, 1695–1702. [CrossRef] [PubMed]

44. Castellanos-Gutiérrez, A.; Sánchez-Pimienta, T.G.; Carriquiry, A.; da Costa, T.H.M.; Ariza, A.C. Higher dietary magnesium intake is associated with lower body mass index, waist circumference and serum glucose in Mexican adults. *Nutr. J.* **2018**, *17*, 114. [CrossRef] [PubMed]

45. Fang, X.; Wang, K.; Han, D.; He, X.; Wei, J.; Zhao, L.; Imam, M.U.; Li, Y.; Xu, Y.; et al. Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: A dose-response meta-analysis of prospective cohort studies. *BMC Med.* **2016**, *14*, 210. [CrossRef]

46. Fang, X.; Liang, C.; Li, M.; Montgomery, S.; Fall, K.; Asaeth, J.; Cao, Y. Dose-response relationship between dietary magnesium intake and cardiovascular mortality: A systematic review and dose-based meta-regression analysis of prospective studies. *J. Trace Elem. Med. Biol.* **2016**, *38*, 64–73. [CrossRef] [PubMed]

47. Rooney, M.R.; Rudser, K.D.; Alonso, A.; Harnack, L.; Saenger, A.K.; Lutsey, P.L. Circulating Ionized Magnesium: Comparisons with Circulating Total Magnesium and the Response to Magnesium Supplementation in a Randomized Controlled Trial. *Nutrients* **2020**, *12*, 263. [CrossRef]

48. Serizawa, N.; Nishimuta, M.; Kodama, N.; Shimada, M.; Yoshitake, Y.; Hongu, N.; Ota, M.; Yano, T. Salt Restriction Affects the Excretions of Minerals (Na, K, Ca, Mg, P and Zn) in the Second Voided Fasting Early Morning Urine. *J. Nutr. Sci. Vitaminol.* **2019**, *65*, 142–147. [CrossRef]

49. Xiong, W.; Liang, Y.; Li, X.; Liu, G.; Wang, Z. A Direct Quantitative Analysis of Erythrocyte Intracellular Ionized Magnesium in Physiological and Pathological Conditions. *Biol. Pharm. Bull.* **2019**, *42*, 357–364. [CrossRef]

50. Blaine, J.; Chonchol, M.; Levi, M. Renal control of calcium, phosphate, and magnesium homeostasis. *Clin. J. Am. Soc. Nephrol.* **2015**, *10*, 1257–1272. [CrossRef]

51. Wu, J.; Xun, P.; Tang, Q.; Cai, W.; He, K. Circulating magnesium levels and incidence of coronary heart diseases, hypertension, and type 2 diabetes mellitus: A meta-analysis of prospective cohort studies. *Nutr. J.* **2017**, *16*, 60. [CrossRef] [PubMed]

52. Rodrigues, A.K.; Melo, A.E.; Domingueti, C.P. Association between reduced serum levels of magnesium and the presence of poor glycemic control and complications in type 1 diabetes mellitus: A systematic review and meta-analysis. *Diabetes Metab. Syndr.* **2020**, *14*, 127–134. [CrossRef] [PubMed]
53. Rodríguez-Ortiz, M.E.; Gómez-Delgado, F.; Arenas de Larriva, A.P.; Canalejo, A.; Gómez-Luna, P.; Herencia, C.; López-Moreno, J.; Rodríguez, M.; López-Miranda, J.; Almadén, Y. Serum Magnesium is associated with Carotid Atherosclerosis in patients with high cardiovascular risk (CORDIOPREV Study). *Sci. Rep.* **2019**, *9*, 8013. [CrossRef]

54. Lecube, A.; Baena-Fustegueras, J.A.; Fort, J.M.; Pelegrí, D.; Hernández, C.; Simó, R. Diabetes is the main factor accounting for hypomagnesemia in obese subjects. *PLoS ONE* **2012**, *7*, e30599. [CrossRef] [PubMed]

55. Liu, A.; Xu, P.; Gong, C.; Zhu, Y.; Zhang, H.; Nie, W.; Zhou, X.; Liang, X.; Xu, Y.; Huang, C.; et al. High serum concentration of selenium, but not calcium, cobalt, copper, iron, and magnesium, increased the risk of both hyperglycemia and dyslipidemia in adults: A health examination center based cross-sectional study. *J. Trace Elem. Med. Biol.* **2020**, *59*, 126470. [CrossRef] [PubMed]

56. Spiga, R.; Mannino, G.C.; Mancuso, E.; Averta, C.; Paone, C.; Rubino, M.; Sciacqua, A.; Succurro, E.; Perticone, F.; Andreozzi, F.; et al. Are Circulating Mg2+ Levels Associated with Glucose Tolerance Profiles and Incident Type 2 Diabetes? *Nutrients* **2019**, *11*, 2460. [CrossRef]

57. Xu, B.; Sun, J.; Deng, X.; Huang, X.; Sun, W.; Xu, Y.; Xu, M.; Lu, J.; Bi, Y. Low serum magnesium level is associated with microalbuminuria in chinese diabetic patients. *Int. J. Endocrinol.* **2013**, *2013*, 580685. [CrossRef]

58. Xu, J.; Xu, W.; Yao, H.; Sun, W.; Zhou, Q.; Cai, L. Associations of serum and urinary magnesium with the pre-diabetes, diabetes and diabetic complications in the Chinese Northeast population. *PLoS ONE* **2013**, *8*, e56750. [CrossRef]

59. Barragán, R.; Colltell, O.; Portolés, O.; Asensio, E.M.; Sorlí, J.V.; Ortega-Azorín, C.; González, J.I.; Sáiz, C.; Fernández-Carrion, R.; Ordovas, J.M.; et al. Bitter, Sweet, Salty, Sour and Umami Taste Perception Decreases with Age: Sex-Specific Analysis, Modulation by Genetic Variants and Taste-Preference Associations in 18 to 80 Year-Old Subjects. *Nutrients* **2018**, *10*, 1539. [CrossRef]

60. Corella, D.; Guillén, M.; Sáiz, C.; Portolés, O.; Sabater, A.; Folch, J.; Ordovas, J.M. Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: Interaction with tobacco smoking and the APOE locus. *J. Lipid Res.* **2002**, *43*, 416–427.

61. Schröder, H.; Fitó, M.; Estruch, R.; Martínez-González, M.A.; Corella, D.; Salas-Salvadó, J.; Lamuela-Raventós, R.; Ros, E.; Salaverría, I.; Fiol, M.; et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. *J. Nutr.* **2011**, *141*, 1140–1145. [CrossRef] [PubMed]

62. Sánchez-González, C.; López-Chaves, C.; Gómez-Aracena, J.; Galindo, P.; Aranda, P.; Llopis, J. Association of plasma manganese levels with chronic renal failure. *J. Trace Elem. Med. Biol.* **2015**, *31*, 78–84. [CrossRef] [PubMed]

63. Joosten, M.M.; Gansevoort, R.T.; Mukamal, K.J.; Kootstra-Ros, J.E.; Feskens, E.J.M.; Geleijnse, J.M.; Navis, G.; Bakker, S.J.L.; The PREVEND Study Group. Urinary Magnesium Excretion and Risk of Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study. *Hypertension* **2013**, *61*, 1161–1167. [CrossRef] [PubMed]

64. Gomers, L.M.M.; Hoenderop, J.G.J.; Bindels, R.J.M.; de Baaij, J.H.F. Hypomagnesemia in Type 2 Diabetes: A Vicious Circle? *Diabetes* **2016**, *55*, 3–13. [CrossRef] [PubMed]

65. Pham, P.C.; Pham, P.A.; Pham, S.V.; Pham, P.T.; Pham, P.M.; Pham, P.T. Hypomagnesemia: A clinical perspective. *Int. J. Nephrol. Renovasc. Dis.* **2014**, *7*, 219–230. [CrossRef] [PubMed]

66. Ilich, J.Z.; Blanusa, M.; Orlič, Z.C.; Orct, T.; Kostial, K. Comparison of calcium, magnesium, sodium, potassium, zinc, and creatinine concentration in 24-h and spot urine samples in women. *Clin. Chem. Lab. Med.* **2009**, *47*, 216–221. [CrossRef] [PubMed]

67. Zhang, T.; Chang, X.; Liu, W.; Li, X.; Wang, F.; Huang, L.; Liao, S.; Liu, X.; Zhang, Y.; Zhao, Y. Comparison of sodium, potassium, calcium, magnesium, zinc, copper and iron concentrations of elements in 24-h urine and spot urine in hypertensive patients with healthy renal function. *J. Trace Elem. Med. Biol.* **2017**, *44*, 104–108. [CrossRef]

68. Hong, Y.H.; Dublin, N.; Razack, A.H.; Mohd, M.A.; Husain, R. Twenty-four hour and spot urine metabolic evaluations: Correlations versus agreements. *Urology* **2010**, *75*, 1294–1298. [CrossRef]

69. Liebscher, D.-H.; Liebscher, D.-E. About the misdiagnosis of magnesium deficiency. *J. Am. Coll. Nutr.* **2004**, *23*, 7308–7315. [CrossRef]
70. Rodríguez-Moran, M.; Guerrero-Romero, F. Hypomagnesemia and prehypertension in otherwise healthy individuals. *Eur. J. Intern. Med.* 2014, 25, 128–131. [CrossRef]

71. Azem, R.; Daou, R.; Bassil, E.; Anvari, E.M.; Taliercio, J.J.; Arrigain, S.; Schold, J.D.; Vachharajani, T.; Nally, J.; Na Khoul, G.N. Serum magnesium, mortality and disease progression in chronic kidney disease. *BMC Nephrol.* 2020, 21, 49. [CrossRef]

72. Park, C.H.; Kim, E.H.; Roh, Y.H.; Kim, H.Y.; Lee, S.K. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: A systematic review and meta-analysis. *PLoS ONE* 2014, 9, e112558. [CrossRef] [PubMed]

73. Peters, K.E.; Chubb, S.A.P.; Davis, W.A.; Davis, T.M.E. The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: The Fremantle Diabetes Study. *PLoS ONE* 2013, 8, e74355. [CrossRef] [PubMed]

74. Pham, P.C.T.; Pham, P.M.T.; Pham, S.V.; Miller, J.M.; Pham, P.T.T. Hypomagnesemia in patients with type 2 diabetes. *Clin. J. Am. Soc. Nephrol.* 2007, 2, 366–373. [CrossRef] [PubMed]

75. Khan, L.A.; Alam, A.M.; Ali, L.; Goswami, A.; Hassan, Z.; Sattar, S.; Banik, N.G.; Khan, A.K. Serum and urinary magnesium in young diabetic subjects in Bangladesh. *Am. J. Clin. Nutr.* 1999, 69, 70–73. [CrossRef]

76. Ahmed, F.; Mohammed, A. Magnesium: The Forgotten Electrolyte-A Review on Hypomagnesemia. *Med. Sci.* 2019, 7, 56. [CrossRef]

77. Čabarkapa, V.; Đerić, M.; Todorović, M.; Sudji, J.; Ilinić, B.; Trifu, A.; Davidović, S. Hypomagnesemia in adults of northern Serbia: Prevalence, nutritional risk factors, and associated comorbidities. *Magnes. Res.* 2019, 32, 25–36.

78. Martin, H.E.; Wertman, M. Serum Potassium, Magnesium, and Calcium Levels in Diabetic Acidosis. *J. Clin. Investig.* 1947, 26, 217–228. [CrossRef]

79. van Orten-Luiten, A.C.B.; Janse, A.; Verspoor, E.; Brouwer-Brolsma, E.M.; Witkamp, R.F. Drug use is associated with lower plasma magnesium levels in geriatric outpatients; possible clinical relevance. *Clin. Nutr.* 2019, 38, 2668–2676. [CrossRef]

80. Famularo, G.; Gasbarrone, L.; Minisola, G. Hypomagnesemia and proton-pump inhibitors. *Expert Opin. Drug Saf.* 2013, 12, 709–716. [CrossRef] [PubMed]

81. Bouras, H.; Roig, S.R.; Kurstjens, S.; Tack, C.J.J.; Kebieche, M.; de Baaij, J.H.F.; Hoenderop, J.G.J. Metformin regulates TRPM6, a potential explanation for magnesium imbalance in type 2 diabetes patients. *Can. J. Physiol. Pharmacol.* 2020. [CrossRef] [PubMed]

82. Kao, W.H.; Folsom, A.R.; Nieto, F.J.; Mo, J.P.; Watson, R.L.; Brancati, F.L. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: The Atherosclerosis Risk in Communities Study. *Arch. Intern. Med.* 1999, 159, 2151–2159. [CrossRef]

83. Guerrero-Romero, F.; Rascón-Pacheco, R.A.; Rodríguez-Morán, M.; de la Peña, J.E.; Wacher, N. Hypomagnesaemia and risk for metabolic glucose disorders: A 10-year follow-up study. *Eur. J. Clin. Investig.* 2008, 38, 389–396. [CrossRef] [PubMed]

84. Kieboom, B.C.T.; Ligthart, S.; Dehghan, A.; Kurstjens, S.; de Baaij, J.H.F.; Hoenderop, J.G.J. Metformin regulates TRPM6, a potential explanation for magnesium imbalance in type 2 diabetes patients. *Diabetologia* 2017, 60, 843–853. [CrossRef]

85. Fang, X.; Han, H.; Li, M.; Liang, C.; Fan, Z.; Aaseth, J.; Montgomery, S.; Cao, Y. Dose-Response Relationship between Dietary Magnesium Intake and Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Regression Analysis of Prospective Cohort Studies. *Nutrients* 2016, 8, 739. [CrossRef]

86. Bertinato, J.; Wang, K.C.; Hayward, S. Serum Magnesium Concentrations in the Canadian Population and Associations with Diabetes, Glycemic Regulation, and Insulin Resistance. *Nutrients* 2017, 9, 296. [CrossRef]

87. Viering, D.H.H.M.; de Baaij, J.H.F.; Walsh, S.B.; Kleta, R.; Bockenhauer, D. Genetic causes of hypomagnesemia, a clinical overview. *Pediatr. Nephrol.* 2017, 32, 1123–1135. [CrossRef]

88. Corre, T.; Arjona, F.J.; Hayward, C.; Youhana, S.; de Baaij, J.H.F.; Belge, H.; Nägele, N.; Debaix, H.; Blanchard, M.G.; Traglia, M.; et al. Genome-Wide Meta-Analysis Unravels Interactions between Magnesium Homeostasis and Metabolic Phenotypes. *J. Am. Soc. Nephrol.* 2018, 29, 335–348. [CrossRef]

89. Chiuve, S.E.; Korngold, E.C.; Januzzi, J.L.; Gantzzer, M.L.; Albert, C.M. Plasma and dietary magnesium and risk of sudden cardiac death in women. *Am. J. Clin. Nutr.* 2011, 93, 253–260. [CrossRef]
90. Ma, J.; Folsom, A.R.; Melnick, S.L.; Eckfeldt, J.H.; Sharrett, A.R.; Nabulsi, A.A.; Hutchinson, R.G.; Metcalf, P.A. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: The ARIC study. Atherosclerosis Risk in Communities Study. J. Clin. Epidemiol. 1995, 48, 927–940. [CrossRef]

91. Bahreini, N.; Gharipour, M.; Khosravi-Boroujeni, H.; Rouhi-Boroujeni, H.; Shiranian, A.; Salehi-Abargouei, A.; Sharifzadeh, G. Pivotal role of mediterranean dietary regimen in the increase of serum magnesium concentration in patients with coronary artery disease. J. Nutr. Metab. 2013, 2013, 431070. [CrossRef] [PubMed]

92. Michos, E.D.; McEvoy, J.W.; Blumenthal, R.S. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. N. Engl. J. Med. 2019, 381, 1557–1567. [CrossRef] [PubMed]

93. Zhao, L.; Hu, M.; Yang, L.; Xu, H.; Song, W.; Qian, Y.; Zhao, M. Quantitative Association between Serum/Dietary Magnesium and Cardiovascular Disease/Coronary Heart Disease Risk: A Dose-Response Meta-analysis of Prospective Cohort Studies. J. Cardiovasc. Pharmacol. 2019, 74, 516–527. [CrossRef] [PubMed]

94. Shahbah, D.; Hassan, T.; Morsy, S.; Saadany, H.E.; Fathy, M.; Al-Ghobashy, A.; Elsamad, N.; Emam, A.; Elhewala, A.; Ibrahim, B.; et al. Oral magnesium supplementation improves glycemic control and lipid profile in children with type 1 diabetes and hypomagnesaemia. Medicine 2017, 96, e6352. [CrossRef]

95. Shahbah, D.; El Naga, A.A.; Hassan, T.; Zakaria, M.; Beshir, M.; Al Morshedy, S.; Abdalhady, M.; Kamel, E.; Rahman, D.A.; Kamel, L.; et al. Status of serum magnesium in Egyptian children with type 1 diabetes and its correlation to glycemic control and lipid profile. Medicine 2016, 95, e5166. [CrossRef]

96. Rasheed, H.; Elahi, S.; Ajaz, H. Serum magnesium and atherogenic lipid fractions in type II diabetic patients of Lahore, Pakistan. Biol. Trace Elem. Res. 2012, 148, 165–169. [CrossRef]

97. Wang, Y.; Wei, J.; Zeng, C.; Yang, T.; Li, H.; Cui, Y.; Xie, D.; Xu, B.; Liu, Z.; Li, J.; et al. Association between serum magnesium concentration and metabolic syndrome, diabetes, hypertension and hyperuricaemia in knee osteoarthritis: A cross-sectional study in Hunan Province, China. BMJ Open 2018, 8, e019159. [CrossRef]

98. Robles, N.R.; Escola, J.M.; Albarran, L.; Espada, R. Correlation of serum magnesium and serum lipid levels in hemodialysis patients. Nephron 1998, 78, 118–119. [CrossRef]

99. Waanders, F.; Dullaart, R.P.F.; Vos, M.J.; Hendriks, S.H.; van Goor, H.; Bilo, H.J.G.; van Dijk, P.R. Hypomagnesaemia and its determinants in a contemporary primary care cohort of persons with type 2 diabetes. Endocrine 2020, 67, 80–86. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).